Skip to main content
SpringerLink
Log in

New Drugs for Alopecias

  • Chapter
  • First Online:
Hair and Scalp Treatments

  • 1465 Accesses

Abstract

The new drugs in the development of AGA include PGF2 analogs, a PGD2 receptor antagonist, Wnt pathway activators, an androgen receptor antagonist, a topical JAK inhibitors, and topical finasteride. While many of these have already shown efficacy compared to placebo, none have shown superiority to topical minoxidil; however, they may still have future as an adjuvant treatment with topical minoxidil. For AA, oral JAK inhibitors are a promising new development, although other new drugs are in development as well. A particularly interesting one is BNZ-1, which has the potential to suppress the autoimmune response without causing systemic immunosuppression.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lolli F, Pallotti F, Rossi A, Fortuna MC, Caro G, Lenzi A, et al. Androgenetic alopecia: a review. Endocrine. 2017;57(1):9–17. https://doi.org/10.1007/s12020-017-1280-y.

    Article  CAS  PubMed  Google Scholar 

  2. Blumeyer A, Tosti A, Messenger A, Reygagne P, Del Marmol V, Spuls PI, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011;9:S1–S57. https://doi.org/10.1111/j.1610-0379.2011.07802.x.

    Article  PubMed  Google Scholar 

  3. Jaworsky C, Kligman AM, Murphy GF. Characterization of inflammatory infiltrates in male pattern alopecia: implications for pathogenesis. Br J Dermatol. 1992;127(3):239–46. http://www.ncbi.nlm.nih.gov/pubmed/1390168. Accessed 3 Nov 2018.

    Article  CAS  PubMed  Google Scholar 

  4. Law SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol. 2010;4:349–58. http://www.ncbi.nlm.nih.gov/pubmed/20463804. Accessed 3 Nov 2018.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Blume-Peytavi U, Lönnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012;66(5):794–800. https://doi.org/10.1016/j.jaad.2011.05.026.

    Article  CAS  PubMed  Google Scholar 

  6. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002;47(Suppl 1):S185–202. http://www.ncbi.nlm.nih.gov/pubmed/12204716. Accessed 29 Nov 2018.

    Article  PubMed  Google Scholar 

  7. Duke University. Topical Bimatoprost effect on androgen dependent hair follicles. In: ClinicalTrials.gov. Bethesda: National Library of Medicine (US); 2000. https://clinicaltrials.gov/ct2/show/NCT01325350 NLM Identifier: NCT01325350. Accessed 3 Nov 2018.

    Google Scholar 

  8. Allergan. Safety and efficacy study of Bimatoprost in the treatment of men with Androgenic Alopecia. In: ClinicalTrials.gov. Bethesda: National Library of Medicine (US); 2000. https://clinicaltrials.gov/ct2/show/results/NCT01325337 NLM Identifier: NCT01325337. Accessed 3 Nov 2018.

    Google Scholar 

  9. Allergan A. Safety and efficacy study of Bimatoprost in men with Androgenic Alopecia (AGA). In: ClinicalTrials.gov. Bethesda: National Library of Medicine (US); 2000. https://clinicaltrials.gov/ct2/show/results/NCT01904721 NLM Identifier: NCT01904721. Accessed 3 Nov 2018.

    Google Scholar 

  10. Allergan. Safety and efficacy study of Bimatoprost in the treatment of women with female pattern hair loss. In: ClinicalTrials.gov. Bethesda: National Library of Medicine (US); 2000. https://clinicaltrials.gov/ct2/show/results/NCT01325350 NLM Identifier: NCT01325350. Accessed 3 Nov 2018.

    Google Scholar 

  11. Talavera-Adame D, Newman D, Newman N. Conventional and novel stem cell based therapies for androgenic alopecia. Stem Cells Cloning. 2017;10:11–9. https://doi.org/10.2147/SCCAA.S138150.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012;4(126):126ra34. https://doi.org/10.1126/scitranslmed.3003122.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Ratner P, Andrews CP, Hampel FC, Martin B, Mohar DE, Bourrelly D, et al. Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from phase 2 and phase 3 randomized, double-blind, placebo- and active-referenced studies. Allergy, Asthma Clin Immunol. 2017;13(1):18. https://doi.org/10.1186/s13223-017-0183-z.

    Article  CAS  Google Scholar 

  14. Premanand A, Reena Rajkumari B. Androgen modulation of Wnt/β-catenin signaling in androgenetic alopecia. Arch Dermatol Res. 2018;310(5):391–9. https://doi.org/10.1007/s00403-018-1826-8.

    Article  CAS  PubMed  Google Scholar 

  15. Samumed. Monthly Newsletter, August 2018. https://www.samumed.com/medium/image/monthly-newsletter-2018-7_387/view.aspx. Accessed 2 Nov 2018.

  16. Yazici Y, Swearingen CJ, Simsek I, DiFrancesco A, Hood JD. Safety, tolerability and efficacy of a topical treatment (SM04554) for Androgenetic Alopecia (AGA): results from a phase 2 trial. In: Poster session presented at: American Academy of Dermatology (AAD). Washington, D.C; 2016 March 04-08.

    Google Scholar 

  17. Seykora J, Simsek I, DiFrancesco A, Swearingen C, Yazici Y. Safety and biopsy outcomes of a topical treatment (SM04554) for Male Androgenetic Alopecia (AGA): results from a phase 2, multicenter, randomized, double-blind, vehicle-controlled trial. In: Poster session presented at: American Academy of Dermatology (AAD). Orlando; 2017 March 03-07.

    Google Scholar 

  18. Cassiopea. Creating Innovation in Dermatology. In: Presented at: Jefferies global health care conference; 2016 June 9; New York. http://www.cassiopea.com/~/media/Files/C/Cassiopea/presentations/Jefferies_GHCC_Jun2016.pdf.

  19. Cassiopea. Breezula. http://www.cassiopea.com/activities/product-pipeline/breezula.aspx. Accessed 2 Nov 2018.

  20. Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv. 2015;1(9):e1500973. https://doi.org/10.1126/sciadv.1500973.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22–8. https://doi.org/10.1016/j.jaad.2016.09.007.

    Article  CAS  PubMed  Google Scholar 

  22. Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016;54(1):19–27. https://doi.org/10.5414/CP202467.

    Article  CAS  PubMed  Google Scholar 

  23. Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78(1):1–12. https://doi.org/10.1016/j.jaad.2017.04.1141.

    Article  PubMed  Google Scholar 

  24. Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166(5):916–26. https://doi.org/10.1111/j.1365-2133.2012.10955.x.

    Article  CAS  PubMed  Google Scholar 

  25. Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–44. https://doi.org/10.1016/j.jaad.2016.12.005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Renert-Yuval Y, Guttman-Yassky E. The changing landscape of Alopecia Areata: the therapeutic paradigm. Adv Ther. 2017;34(7):1594–609. https://doi.org/10.1007/s12325-017-0542-7.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–9. https://doi.org/10.1038/nm.3645.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Ghoreschi K, Gadina M. Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp Dermatol. 2014;23(1):7–11. https://doi.org/10.1111/exd.12265.

    Article  CAS  PubMed  Google Scholar 

  29. Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790. https://doi.org/10.1172/jci.insight.89790.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776. https://doi.org/10.1172/jci.insight.89776.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Jabbari A, Sansaricq F, Cerise J, Chen JC, Bitterman A, Ulerio G, et al. An open-label pilot study to evaluate the efficacy of Tofacitinib in moderate to severe patch-type Alopecia Areata, Totalis, and Universalis. J Invest Dermatol. 2018;138(7):1539–45. https://doi.org/10.1016/j.jid.2018.01.032.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Olsen E, Hordinsky M, McDonald-Hull S, Price V, Roberts J, Shapiro J, et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol. 1999;40(2):242–6. https://doi.org/10.1016/S0190-9622(99)70195-7.

    Article  CAS  PubMed  Google Scholar 

  33. Almohanna HM, Perper M, Tosti A. Safety concerns when using novel medications to treat alopecia. Expert Opin Drug Saf. 2018;17(11):1115–28. https://doi.org/10.1080/14740338.2018.1533549.

    Article  CAS  PubMed  Google Scholar 

  34. Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016;74(5):841–50. https://doi.org/10.1016/j.jaad.2016.01.013.

    Article  CAS  PubMed  Google Scholar 

  35. Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016;75(5):831–41. https://doi.org/10.1136/annrheumdis-2014-205847.

    Article  CAS  PubMed  Google Scholar 

  36. Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016;18(1):34. https://doi.org/10.1186/s13075-016-0932-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol. 2017;77(1):167–70. https://doi.org/10.1016/j.jaad.2017.03.024.

    Article  PubMed  Google Scholar 

  38. Ocampo-Garza J, Griggs J, Tosti A. New drugs under investigation for the treatment of alopecias. Expert Opin Investig Drugs. 2019. In Press; https://doi.org/10.1080/13543784.2019.1568989.

    Article  CAS  PubMed  Google Scholar 

  39. Happle R, Hausen BM, Wiesner-Menzel L. Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol. 1983;63(1):49–52. http://www.ncbi.nlm.nih.gov/pubmed/6191489. Accessed 3 Nov 2018.

    CAS  PubMed  Google Scholar 

  40. Lamb RC, Young D, Holmes S. Retrospective review of diphencyprone in the treatment of alopecia areata. Clin Exp Dermatol. 2016;41(4):352–8. https://doi.org/10.1111/ced.12776.

    Article  CAS  PubMed  Google Scholar 

  41. Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med. 2012;366(16):1515–25. https://doi.org/10.1056/NEJMra1103442.

    Article  CAS  PubMed  Google Scholar 

  42. Katikaneni R, Seymour AW, Gulati R, Ponnapakkam T, Gensure RC. Therapy for Alopecia Areata in mice by stimulating the hair cycle with parathyroid hormone agonists linked to a collagen-binding domain. J Investig Dermatol Symp Proc. 2015;17(2):13–5. https://doi.org/10.1038/jidsymp.2015.32.

    Article  CAS  PubMed  Google Scholar 

  43. Venten I, Hess N, Hirschmüller A, Altmeyer P, Brockmeyer N. Treatment of therapy-resistant Alopecia areata with fumaric acid esters. Eur J Med Res. 2006;11(7):300–5. http://www.ncbi.nlm.nih.gov/pubmed/16899425. Accessed 3 Nov 2018.

    CAS  PubMed  Google Scholar 

  44. Ursini F, Russo E, De Giorgio R, De Sarro G, D’Angelo S. Current treatment options for psoriatic arthritis: spotlight on abatacept. Ther Clin Risk Manag. 2018;14:1053–9. https://doi.org/10.2147/TCRM.S148586.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Blair HA, Deeks ED. Abatacept: a review in rheumatoid arthritis. Drugs. 2017;77(11):1221–33. https://doi.org/10.1007/s40265-017-0775-4.

    Article  CAS  PubMed  Google Scholar 

  46. Magdaleno-Tapial J, Valenzuela-Oñate C, Sánchez-Carazo JL, Alegre-de Miquel V. Improvement of alopecia areata with apremilast. Australas J Dermatol. 2018; https://doi.org/10.1111/ajd.12934.

    Article  PubMed  Google Scholar 

  47. Keren A, Shemer A, Ullmann Y, Paus R, Gilhar A. The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo. J Dermatol Sci. 2015;77(1):74–6. https://doi.org/10.1016/j.jdermsci.2014.11.009.

    Article  CAS  PubMed  Google Scholar 

  48. Liu LY, King BA. Lack of efficacy of apremilast in 9 patients with severe alopecia areata. J Am Acad Dermatol. 2017;77(4):773–4. https://doi.org/10.1016/j.jaad.2017.05.034.

    Article  PubMed  Google Scholar 

  49. Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe Atopic Dermatitis. N Engl J Med. 2014;371(2):130–9. https://doi.org/10.1056/NEJMoa1314768.

    Article  CAS  PubMed  Google Scholar 

  50. Penzi LR, Yasuda M, Manatis-Lornell A, Hagigeorges D, Senna MM. Hair regrowth in a patient with long-standing Alopecia Totalis and Atopic Dermatitis treated with Dupilumab. JAMA Dermatol. 2018; https://doi.org/10.1001/jamadermatol.2018.2976.

    Article  PubMed  Google Scholar 

  51. Mitchell K, Levitt J. Alopecia areata after dupilumab for atopic dermatitis. JAAD Case Rep. 2018;4(2):143–4. https://doi.org/10.1016/j.jdcr.2017.11.020.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Iftikhar IH, Schimmel M, Bender W, Swenson C, Amrol D. Comparative efficacy of Anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma: a network meta-analysis. Lung. 2018;196(5):517–30. https://doi.org/10.1007/s00408-018-0151-5.

    Article  CAS  PubMed  Google Scholar 

  53. Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, et al. Treatment of atopic dermatitis with tralokinumab, an Anti–IL-13 mAb. J Allergy Clin Immunol. 2018; https://doi.org/10.1016/j.jaci.2018.05.029.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Leonard M. Miller School of Medicine, Miami, FL, USA

    Jacob Griggs

  2. Department of Dermatology Santa Casa da Misericordia, Rio De Janeiro, Brazil

    Rodrigo Pirmez

  3. Fredric Brandt Endowed Professor of Dermatology, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA

    Antonella Tosti

Authors
  1. Jacob Griggs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rodrigo Pirmez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonella Tosti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacob Griggs .

Editor information

Editors and Affiliations

  1. Fredric Brandt Endowed, Professor of Dermatology, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA

    Antonella Tosti

  2. Dermatoncology & Trichology Clinic, National University of Mexico, Mexico City, Mexico

    Daniel Asz-Sigall

  3. Department of Dermatology, Santa Casa da Misericordia, Rio De Janeiro, Brazil

    Rodrigo Pirmez

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Griggs, J., Pirmez, R., Tosti, A. (2020). New Drugs for Alopecias. In: Tosti, A., Asz-Sigall, D., Pirmez, R. (eds) Hair and Scalp Treatments. Springer, Cham. https://doi.org/10.1007/978-3-030-21555-2_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-21555-2_22

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-21554-5

  • Online ISBN: 978-3-030-21555-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation